COSCIENS Biopharma Inc T.CSCI

Cancer Cachexia

[prophetoffactz]

AEZS has run a small pilot study on macimorelin to treat cancer cachexia. "Roughly 19.3 million people globally were diagnosed with cancer in 2020. 1 More than half of these patients will experience unintentional weight loss due to cancerrelated changes in appetite and metabolic processes, known as cachexia 2 with an 86% incidence of weight loss 1–2 weeks prior to cancerrelated death. 3 Cachexia is defined as ‘an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. "

Here was the published conclusion concerning a small pilot study:

"Daily oral macimorelin for 1 week was safe and numerically improved body weight and QOL in patients with cancer cachexia compared with placebo. Longer term administration should be evaluated for mitigation of cancerinduced reductions in body weight, appetite and QOL in larger studies." Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia - PMC (nih.gov)

Yeast beta glucan can provide immune support and could act as a drug delivery technology so I asked...

Based on the available information, combining macimorelin with yeast beta-glucan produced using Ceapro's PGX technology could potentially offer several benefits for treating cancer cachexia:

1. Controlled release: Impregnating macimorelin into the porous structure of yeast beta-glucan particles could allow for a controlled, sustained release of the drug. This may enable higher doses to be administered while reducing side effects.
2. Improved bioavailability: The beta-glucan particles could potentially enhance absorption and bioavailability of macimorelin, allowing for more effective delivery.
3. Immune support: Yeast beta-glucans have shown immunomodulatory effects that could provide additional benefits for cancer patients. Recent studies have demonstrated their ability to stimulate anti-tumor immune responses.
4. Synergistic effects: The combination of macimorelin's effects on appetite/weight gain and beta-glucan's immune-boosting properties could potentially have synergistic benefits for cancer cachexia patients.
5. Safety profile: Both macimorelin and yeast beta-glucans have shown good safety profiles in clinical studies, suggesting this combination approach may be well-tolerated.
6. Addressing multiple aspects: This approach could potentially address both the metabolic/nutritional aspects of cachexia (via macimorelin) and immune dysfunction (via beta-glucans) simultaneously.

While this combination appears promising in theory, it's important to note that clinical studies would be needed to confirm the safety and efficacy of this specific approach for cancer cachexia. The recent positive results with macimorelin alone and the immune-enhancing effects of yeast beta-glucans provide a rationale for further investigation of this combined strategy.

Share

Rewrite